Leinco Technologies and CellCarta partner to advance proteomics in immuno-oncology

The combined offering is designed to support a wide range of applications, from pilot-scale research to high-volume clinical use

ModeX doses first patients in trial of next-gen T-cell engager for aggressive B-cell lymphoma

The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack

Pfizer unleashes wave of breakthrough cancer data at ASCO 2026

Pharma giant targets new standards of care

Leinco and CellCarta team up to power next-gen proteomics for cancer and targeted therapies

Together, the companies aim to deliver an integrated toolkit for biomarker discovery and clinical research

ENSPRYNG cuts MOGAD relapse risk by 68% in landmark Phase III trial: Roche

The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents

Samsung Bioepis unveils promising preclinical data for novel ADC SBE303 at AACR 2026

SBE303 targets Nectin-4, an adhesion protein overexpressed in multiple tumor types, including urothelial, lung, and breast cancers

AWS unveils Amazon Bio Discovery to accelerate drug design with AI

Merck bags EU nod for infant RSV protection in major public health milestone

ENFLONSIA is a long-acting monoclonal antibody designed to shield infants through a typical five-month RSV season with a single, fixed dose

Piramal Pharma, Ajinomoto Bio-Pharma collaborate to accelerate ADC development

Collaboration integrates AJICAP™ technology with global manufacturing capabilities to streamline antibody-drug conjugate pipelines

GlycoNex wins Japan nod to launch first human trial of lead program in gastrointestinal cancers

The upcoming multi-center, multinational Phase 1 study will evaluate safety, tolerability, pharmacokinetics, and early signs of efficacy